May 13, 2021 / 06:00PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Okay. Good afternoon. And welcome to the final day of the BofA Healthcare Conference, Virtual Vegas, as it were. My name is Geoff Meacham. I'm a senior biopharma analyst here at BofA. And I have Jason Zemansky from my team with me as well. And we're thrilled to have CFO, Andy Dickinson from Gilead. Andy, welcome.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Thank you. Thanks for having me. Appreciate it once again.
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Yes. So what we'll do is, we'll do some questions here with Andy. We won't get into anything post the quarter. Obviously, we've talked about that a week or so ago. But let's get right into it, Andy.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystWhen you think about the HIV business. It's a flagship
Trustpilot
